USA – FDA updates guidance on promotional labeling and advertising of biosimilars
Year: 2024
Type: other
Abstract: The US Food and Drug Administration (FDA) has published revised guidance on promotional labeling and advertising for prescription biosimilar drugs and their reference products. The agency issued the draft guidance – Promotional labeling and advertising considerations for prescription biological reference products, biosimilar products, and interchangeable biosimilar products: Questions and answers – on 24 April and will accept comments through 25 June. The document was designed to address ind...
Source: OpenEdition (OpenEdition)
DOI: 10.58079/12f6u
Author: Vroby
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W6936467555
Cites:
Cited by:
Related to: